Search results
Results from the WOW.Com Content Network
However, another more recent study found that Paxlovid does not reduce the risk. Since Paxlovid is still a relatively new drug and the COVID-19 virus is still changing, it may take some time for a ...
The Covid antiviral Paxlovid can reduce the risk of hospitalization or death. But there are potential downsides to the medication. As Covid cases rise, what to know about Paxlovid
Pfizer's drug Paxlovid on display in Pembroke Pines, Fla., on July 7, 2022. Credit - Joe Raedle—Getty Images. T aking the COVID-19 antiviral Paxlovid does not appear to improve Long COVID ...
The antiviral drug can protect some groups from getting severely ill with Covid. Here's what you should know about it.
Yet there is wide documentation of the low frequency of prescribing Paxlovid and other antivirals, and that can have significant consequences for higher-risk COVID-19 patients.
A study published in March 2023 reported that treatment with nirmatrelvir within five days of initial infection reduced the risk of long COVID relative to patients who did not receive Paxlovid. [ 31 ]
Paxlovid prevents the coronavirus from replicating, so researchers think it may also reduce the risk of an infection causing inflammation or organ damage, which in turn can lead to chronic illness.
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [20] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [ 21 ]